FCMI
DNLI icon

Foresite Capital Management IV’s Denali Therapeutics DNLI Stock Holding History

Foresite Capital Management IV’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-94,666
Closed -$1.48M – 19
2017
Q4 		$1.48M Buy
+94,666
New +$1.7M 1.04% 12

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Foresite Capital Management IV's DNLI Position: Q1 2018 in Review

Foresite Capital Management IV sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 94,666 shares — an estimated $1.48M sold.

Foresite Capital Management IV first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $1.48M in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

  • Foresite Capital Management IV reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Foresite Capital Management IV sold 94,666 Denali Therapeutics shares in Q1 2018, an estimated $1.48M.
  • Foresite Capital Management IV first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
  • Foresite Capital Management IV's Denali Therapeutics position peaked at $1.48M in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on Foresite Capital Management IV's 13F filing for Q1 2018, filed 15 May 2018.